Roxithromycin, in prevention of acute coronary syndrome Associated with Chlamydia pneumoniae infection: A randomized placebo controlled trial

Journal of the Medical Association of Thailand

Volumn 84, Issue SUPPL. 3, 2001, Pages

  Leowattana, Wattana ^a   Bhuripanyo, Kieartijai ^a   Singhaviranon, Lily ^a   Akaniroj, Surank ^a   Mahanonda, Nithi ^a   Samranthin, Manoon ^a   Pokum, Sasikant ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Acute Coronary Syndrome; Chlamydia pneumoniae; Randomized Placebo Control; Roxithromycin

Indexed keywords

IMMUNOGLOBULIN G; PLACEBO; ROXITHROMYCIN;

ADULT; AGED; ANGINA PECTORIS; ANTIBIOTIC THERAPY; ANTIBODY TITER; ARTICLE; BYPASS SURGERY; CARDIOVASCULAR RISK; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVASCULARIZATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGINA PECTORIS; ANTI-BACTERIAL AGENTS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ROXITHROMYCIN; TREATMENT FAILURE;

EID: 0035561426     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Chlamydia pneumoniae and coronary heart disease
2. Atherosclerosis, inflammation, and infection
3. Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis
4. Fifty per cent of patients with coronary artery disease do not have any of the conventional risk factors
5. The possible role of infections in acute myocardial infarction
6. Infections, inflammation, and the risk of coronary heart disease
7. Chronic infections and coronary heart disease
8. Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus: Chronic infections and coronary heart disease
9. Chlamydia pneumoniae and atherosclerosis - An update
10. Seroepidemiological evidence for an association between Chlamydia pneumoniae and atherosclerosis
11. Chlamydia pneumoniae infection and incident coronary heart disease: The Atherosclerosis Risk in Communities Study
12. The prevalence of Chlamydia pneumoniae antibodies in Thai patients with coronary artery disease
13. Association of seropositivity for Chlamydia pneumoniae and coronary artery disease in heterozygous familial hypercholesterolaemia
14. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms
15. Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s)
16. Lack of association between seropositivity to Chlamydia pneumoniae and carotid atherosclerosis
17. Can an antibiotic (macrolide) prevent Chlamydia pneumoniae-induced atherosclerosis in a rabbit model?
18. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model
19. Chlamydia pneumoniae-induced atherosclerosis in a rabbit model
20. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study
21. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction
22. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study
23. T lymphocyte lines isolated from atheromatous plaque contain cells capable of responding to Chlamydia antigens
24. In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries
25. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model
26. Chlamydia pneumoniae eradication from carotid plaques. Results of an open, randomised treatment study